TerraPower Isotopes Invests $450M in Actinium-225 Production Facility
oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…
AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.
Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Elizabeth Cairns / endpoints - Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study. The triple-G ...
AI Summary: Eli Lilly’s third‑generation GLP‑1 candidate reported Phase 3 data demonstrating significant weight loss and A1C reductions, with efficacy appearing comparable to existing therapies like Mounjaro. The results sharpen competition in the GLP‑1 market and raise questions about pricing, access and who gets first dibs on the next blockbuster injection.
- At clinics: GLP‑1 demand reshaping access, care and pricing (5)
- In labs: oral pills and novel GLP‑1 delivery approaches (4)
- On the ground: Lilly's triple‑G rivaling Mounjaro in trials (3)
- Other: clinical oddities, surgical implications and pipeline setbacks (5)
At clinics: GLP‑1 demand reshaping access, care and pricing
In labs: oral pills and novel GLP‑1 delivery approaches
On the ground: Lilly's triple‑G rivaling Mounjaro in trials
Other: clinical oddities, surgical implications and pipeline setbacks
Verily raises $300M, sheds Alphabet’s majority control
Shelby Livingston / endpoints - Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned exclusively. The funding round was led by Series X Capital ...
AI Summary: Verily secured a $300 million financing round that reduces Alphabet’s majority control, bringing new strategic investors on board including health system partners. The cash infusion aims to accelerate Verily’s healthcare technology and platform ambitions — because nothing says “healthcare disruption” like another well‑funded pivot.
Turquoise Health Snags $40M to Simplify Healthcare Contracts & Payments
Katie Adams / medcitynews - Turquoise Health raised $40 million in a Series C round to expand beyond price transparency into managing healthcare contracts. The startup’s platform aims to simplify payer–provider agreements, reduce administrative waste and enable patients to see guara…
AI Summary: Turquoise Health closed a $40 million funding round to accelerate its platform that standardizes healthcare contracts and payments, aiming to increase price transparency and streamline payer–provider interactions. The cash infusion will support product growth, sales expansion and the company's push to make messy contract data slightly less catastrophic for hospital finance teams.
Why Providence Wants to Sell Its Health Plan
Katie Adams / medcitynews - Providence announced its intent to sell its health plan, exiting the “payvider” model as rising costs and operational complexity weigh on smaller regional insurers. The move reflects a broader trend of health systems refocusing on core care delivery and e…
AI Summary: Providence Healthcare is actively weighing the sale of its health insurance arm as mounting fiscal pressures force leaders to consider dramatic options. The move would reshape the system’s payer-provider footprint, potentially easing balance‑sheet strain while unnerving patients, employers and regulators who’ll suddenly have a stake in the decision.
Lantern Secures $30M to Fuel Growth Across Employers and Health Plans
Marissa Plescia / medcitynews - Lantern’s $30 million raise was led by Morgan Health, a JPMorganChase business unit focused on employer-sponsored healthcare, as well as Echo Health Ventures, a strategic investment platform that invests on behalf of multiple Blues health plans.The post L…
AI Summary: Lantern secured a $30 million investment led by Morgan Health and Echo Health Ventures to scale its employer- and plan-facing digital health platform. The capital will accelerate product development, deepen payer-employer partnerships, and expand deployment of Lantern’s care navigation and benefits tools as it chases broader market traction — because nothing says progress like more tech for paperwork.
Sutter, Allina Health Combine to Form $26B Health System
Katie Adams / medcitynews - Sutter Health is acquiring Allina Health in a deal that would create a $26 billion nonprofit health system spanning California, Minnesota and Wisconsin. The deal reflects a broader wave of hospital consolidation as providers pursue scale to manage rising …
AI Summary: Sutter Health and Allina Health have agreed to combine in a transaction that would create a $26 billion nonprofit system spanning California and Minnesota, forming a 39‑hospital network. The deal aims to consolidate operations and expand market reach, subject to definitive agreements and regulatory approvals, promising scale-driven efficiencies — and inevitably, some rebranded parking lots.
- Close watch: finances, approvals and expected closing timeline (2)
- On the ground: Sutter and Allina agree to $26B merger (3)
- Other developments: regional hospital expansions and financing moves (2)
- Trend watch: consolidation reshaping hospital markets nationwide (2)
- All Other Stories
Close watch: finances, approvals and expected closing timeline
On the ground: Sutter and Allina agree to $26B merger
Other developments: regional hospital expansions and financing moves
Trend watch: consolidation reshaping hospital markets nationwide
All Other Stories
‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug
Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…
AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.
Healthcare tech inovation: Lessons from HIMSS 2026
healthcaredive - At HIMSS 2026, AWS took the stage with Jupiter Medical Center and Rady Children's Health. Read the key lessons from last week's Views from the Top Session.
AI Summary: At HIMSS 2026 vendors and health systems traded demos and earnest promises about real‑time data, cloud pathology and tighter interoperability — with AWS onstage alongside Jupiter Medical Center and Rady Children’s. The practical message: better connectivity and identity tools could finally unstick silos — if hospitals can stomach the integration bill.
- EHR rollouts: Epic expansions, VA launches and outages (6)
- HIMSS: Vendors push real-time data, cloud and interoperability (7)
- Interoperability drama: identity gaps, APIs and improper data access (7)
- OTHER: AI, imaging, workforce and operational healthcare stories (23)
- All Other Stories
EHR rollouts: Epic expansions, VA launches and outages
HIMSS: Vendors push real-time data, cloud and interoperability
Interoperability drama: identity gaps, APIs and improper data access
OTHER: AI, imaging, workforce and operational healthcare stories
All Other Stories
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up
Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
AI Summary: Novo Nordisk has dropped its legal fight with Hims & Hers and struck a business-friendly truce: Hims will sell Novo’s branded weight‑loss medications on its platform. The abrupt move turns courtroom theatrics into commercial collaboration, smoothing distribution while leaving regulators and competitors to enjoy the schadenfreude.
Grail names new CEO as Bob Ragusa retires
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.
Vanderbilt Health president, CEO to retire
Paige Twenter / beckershospitalreview - Jeff Balser, MD, PhD, president and CEO of Vanderbilt Health and dean of Vanderbilt University’s school of medicine, plans to retire from both roles Dec. 31, according to a March 12 news release from the Nashville, Tenn.-based organizations. During his 17…
AI Summary: Jeff Balser, president and CEO of Vanderbilt Health (and dean of Vanderbilt University School of Medicine), will retire at the end of the year, prompting the health system’s board to launch a national search for his successor. Leaders emphasize a careful transition to preserve academic‑clinical stability while navigating complex operational challenges.
Gallup poll: One in three Americans cutting back on daily expenses to pay for healthcare
fiercehealthcare - Healthcare affordability remains a significant challenge, with a third of respondents to a new Gallup poll saying they had to cut back on daily living expenses to afford care.
AI Summary: A Gallup poll reports one-third of Americans trimmed everyday spending, borrowed money or skipped essentials to pay medical bills. The findings highlight acute affordability pressures that force families to choose between care and basic needs, underscoring systemic gaps in coverage and cost control while policymakers offer the usual sympathetic nod.
Universal Health Services buys Talkspace for $835M
Ngai Yeung / endpoints - Universal Health Services, which operates hospitals and mental healthcare facilities, is acquiring Talkspace for $835 million in an area closely watched for consolidation, as virtual mental health companies grapple with falling valuations despite high dem…
AI Summary: Universal Health Services agreed to acquire Talkspace for roughly $835 million to bulk up virtual behavioral‑health capabilities and outpatient telehealth services. The deal aims to expand UHS’s behavioral care footprint and diversify revenue streams, subject to customary closing conditions and regulatory review — because nothing says mental‑health innovation like a corporate merger.
Aetna to pay $117.7M to settle Medicare Advantage upcoding allegations: DOJ
fiercehealthcare - Aetna has agreed to pay $117.7 million to settle allegations that it submitted false or inaccurate diagnoses to juice Medicare Advantage payments.
AI Summary: CVS Health (via its Aetna unit) agreed to a roughly $118 million settlement with the DOJ to resolve False Claims Act allegations that inaccurate diagnosis submissions inflated Medicare Advantage payments. The deal closes a chapter on federal scrutiny of coding practices and aims to avoid years more of litigation and bad headlines.
Leapfrog ordered to remove safety grade for 5 Tenet hospitals
fiercehealthcare - A federal judge said a 2024 methodology update that adjusted the weighting of safety measures inputted for nonparticipating hospitals was "deceptive and unfair" under Florida law. Leapfrog plans to appeal, but said it will be making broader changes in rat…
AI Summary: A federal judge ruled that Leapfrog’s safety grades for five Florida hospitals—primarily Tenet-owned facilities—were based on a methodology the court deemed scientifically unsupported and potentially deceptive. The decision requires Leapfrog to take down those grades, raising fresh questions about the design, transparency and legal defensibility of high-profile hospital safety metrics.
MUSC Health acquires South Carolina's largest multispecialty practice for $111M
fiercehealthcare - The deal, effective March 3, includes 126 physicians and advanced practitioners, expanding the academic system's primary care capacity.
AI Summary: MUSC Health completed a $111 million acquisition of a major South Carolina multispecialty practice, expanding its primary care and outpatient capacity. The deal consolidates regional services under the academic system’s umbrella, promising integrated care and scale efficiencies — and yes, another hospital system just got a bit larger.
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.
Patients with multiple chronic diseases are a looming threat to health systems' financials: Vizient
fiercehealthcare - A recent claims data analysis shows the 11% of people with multiple chronic conditions are behind 52% of inpatient admissions and about a third of outpatient visits. Their projected increases and unfavorable payer mix spell trouble for health systems' bot…
AI Summary: A Vizient analysis shows roughly 11% of the U.S. population accounts for about 52% of hospital admissions, spotlighting how patients with multiple chronic conditions consume disproportionate inpatient resources. The report warns this concentration strains hospital finances and operational capacity, and calls for targeted care models to manage high‑need populations more efficiently.